Reviews/Statins/Statin cardiovascular benefit is primarily mediated through LDL cholesterol reduction
· ST-MEC-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The question is whether statins prevent heart attacks and strokes mainly by lowering LDL cholesterol, rather than through other effects of the drug. The strongest clue in this corpus is consistency: inside a statin trial, the more LDL fell, the fewer events occurred [5], and benefit from inheriting a weaker version of the statin's own target gene tracks the LDL change [16]. Drugs that lower LDL by completely different routes deliver the same amount of protection per unit of LDL lowered [1], and adding more LDL lowering on top of a statin adds more protection [4]. That pattern is what you would expect if LDL reduction is doing the work. But no study here actually measures how much of a statin's benefit comes from LDL versus everything else, so the word 'primarily' is read off this consistency rather than counted directly.
Within a rosuvastatin trial, cardiovascular event rates fell step-wise with greater LDL reduction, from 11.2 down to 4.8 per 1000 person-years across increasing reduction groups [5]. Genetic variation in HMGCR, the statin target, lowers risk in proportion to the LDL and apoB change [16]. When standardised per 1 mmol/L of LDL lowering, bempedoic acid gave an HR of 0.75 (95% CI 0.63-0.90), described as comparable to the 0.78 reported for statins [1]. Adding ezetimibe [4] (HR 0.936) or evolocumab [3] (HR 0.85) to a statin, or using bempedoic acid in statin-intolerant patients [6] (HR 0.87), each produced further benefit from further LDL lowering through non-statin mechanisms. The contested point: The case turns on cross-mechanism consistency rather than a measured partition of statin benefit. Only [5] and [16] bear on statins directly; the randomised evidence [1][3][4][6] establishes that LDL lowering is causal in general but does not isolate the statin mechanism named by the claim, and no eligible paper quantifies the LDL-mediated fraction.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Statins, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Only two eligible papers test statins directly: [5] is a post-hoc within-trial observational analysis and [16] is genetic. The RCT-grade evidence [1][3][4][6] concerns non-statin drugs and establishes LDL-causality generally, not the statin mechanism the claim names.
No primary paper in the corpus partitions statin benefit into LDL-mediated vs non-LDL fractions, so the word 'primarily' is an inference from cross-mechanism consistency rather than a measured mediation estimate.
Where it remains uncertain. Only two papers test statins directly and both are indirect designs [5][16]; [16] also flags that the operative variable may be apoB particle number rather than LDL cholesterol mass.
Aleatory
LDL reduction to a fixed statin dose varies widely across people [5], so the mediation signal is observed against substantial patient-level variability in response.
Epistemic
No eligible primary paper partitions statin benefit into LDL-mediated versus non-LDL fractions; direct statin evidence is limited to a post-hoc analysis [5] and a genetic study [16].
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Benefit per unit LDL-C is the same for statins and a non-statin LDL-lowering drug, arguing the active variable is LDL-C lowering not a statin-specific effect
“When normalized per 1 mmol/L reduction in LDL-C, the HR was 0.75 (95% CI: 0.63-0.90), comparable to the rate ratio of 0.78 reported for statins in the CTTC meta-analysis.”
Panel auditInternal validity: high · scope of inference: Statin-intolerant patients with or at high risk for cardiovascular disease; comparison of LDL-standardized benefit across two agents.Key limitations: benefit inferred via cross-trial standardization, not a head-to-head statin arm · statin-intolerant population
Incremental non-statin LDL-C lowering on a statin background yields incremental benefit, consistent with LDL-C as the mediator
“When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit.”
Panel auditInternal validity: high · scope of inference: Post-acute-coronary-syndrome patients; incremental LDL lowering on a fixed statin dose.Key limitations: small absolute effect (HR 0.936) · tests ezetimibe add-on, not statin mechanism per se
Direct statin (rosuvastatin) dose-response: benefit magnitude tracks the degree of LDL-C reduction within the trial
“These % LDLC reductions directly related to the risks of first cardiovascular events; at trial completion, incidence rates for the primary endpoint were 11.2, 9.2, 6.7, and 4.8 per 1000 person-years for those in the placebo, no LDLC reduction, LDLC reduction <50%, and LDLC reduction ≥50% groups, respectively.”
Panel auditInternal validity: high · scope of inference: Initially healthy primary-prevention men and women on high-intensity rosuvastatin.Key limitations: achieved-LDL subgroups are post-randomization (not randomized) · single statin, primary prevention · observational within the trial
Additional LDL-C lowering beyond statins reduces events, supporting the LDL-causality principle underlying the claim
“In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.”
Panel auditInternal validity: high · scope of inference: Patients with atherosclerotic cardiovascular disease already on statins; incremental LDL lowering by PCSK9 inhibition.Key limitations: evolocumab, not a statin · only indirectly addresses statin mediation · 2.2-year median follow-up
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Strongly convergent primary evidence (statin dose-response, HMGCR genetics, mechanism-consistency) supports LDL-C as the primary mediator, held below Established because 'primarily' is inferred rather than measured and direct statin-specific evidence is limited to two papers.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Formal mediation analysis of statin benefit. The word 'primarily' is inferred, not measured; nothing here partitions statin benefit into LDL-mediated and non-LDL components. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A mediation analysis within a statin outcomes trial estimating the proportion of event reduction explained by on-treatment LDL change.
Open question: What fraction of statin cardiovascular benefit is statistically mediated by LDL cholesterol reduction? Why it is still open: No eligible primary paper measures the mediated fraction; the claim rests on cross-mechanism consistency [1][5][16].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19